These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 36907910)
1. Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer. Xu N; Zhao J; Zhao F; Liu H; Yin W; Zhu S; Nie L; Sun G; Zheng L; Liu Z; Cai D; Chen J; Dai J; Ni Y; Wang Z; Zhang X; Liang J; Chen Y; Hu X; Pan X; Yin X; Zhu X; Zhang Y; Wang Z; Zeng Y; Wang M; Shen P; Chen N; Zeng H J Cancer Res Clin Oncol; 2023 Aug; 149(10):7247-7258. PubMed ID: 36907910 [TBL] [Abstract][Full Text] [Related]
2. AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy. Zhao J; Zhang M; Liu J; Liu Z; Shen P; Nie L; Guo W; Cai D; Liu J; Armstrong CM; Sun G; Chen J; Zhu S; Dai J; Zhang H; Zhao P; Zhang X; Yin X; Zhu X; Ni Y; Chen N; Zeng H Prostate; 2019 Sep; 79(13):1553-1562. PubMed ID: 31294486 [TBL] [Abstract][Full Text] [Related]
3. The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer. Wang Z; Zhu S; Zhao J; Nie L; Chen X; Zhang M; Chen N; Sun G; Chen J; Ni Y; Dai J; Liu Z; Tao R; Zhang X; Zhu X; Zhang H; Liang J; Wang Z; He B; Shen P; Zeng H Prostate; 2021 Nov; 81(15):1191-1201. PubMed ID: 34435696 [TBL] [Abstract][Full Text] [Related]
4. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775 [TBL] [Abstract][Full Text] [Related]
5. Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67. Zhao F; Zhao J; Wei X; Shi Y; Xu N; Zhu S; Chen J; Sun G; Dai J; Wang Z; Zhang X; Liang J; Hu X; Liu H; Zhao J; Liu Z; Nie L; Shen P; Chen N; Zeng H Prostate; 2024 Jul; 84(10):932-944. PubMed ID: 38629249 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038 [TBL] [Abstract][Full Text] [Related]
7. Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis. Farinea G; Calabrese M; Carfì F; Saporita I; Poletto S; Delcuratolo MD; Turco F; Audisio M; Di Stefano FR; Tucci M; Buttigliero C Cells; 2024 Aug; 13(16):. PubMed ID: 39195285 [TBL] [Abstract][Full Text] [Related]
8. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Schweizer MT; Zhou XC; Wang H; Bassi S; Carducci MA; Eisenberger MA; Antonarakis ES Eur Urol; 2014 Oct; 66(4):646-52. PubMed ID: 24491307 [TBL] [Abstract][Full Text] [Related]
9. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637 [TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer. Fan L; Yang Y; Chi C; Ma X; Wang R; Gong Y; Zheng H; Pan J; Zhu Y; Dong B; Xue W Prostate; 2019 May; 79(6):567-573. PubMed ID: 30614033 [TBL] [Abstract][Full Text] [Related]
11. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061 [TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. Yu EY; Kolinsky MP; Berry WR; Retz M; Mourey L; Piulats JM; Appleman LJ; Romano E; Gravis G; Gurney H; Bögemann M; Emmenegger U; Joshua AM; Linch M; Sridhar S; Conter HJ; Laguerre B; Massard C; Li XT; Schloss C; Poehlein CH; de Bono JS Eur Urol; 2022 Jul; 82(1):22-30. PubMed ID: 35397952 [TBL] [Abstract][Full Text] [Related]
13. The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy. Zhao J; Shen P; Sun G; Chen N; Liu J; Tang X; Huang R; Cai D; Gong J; Zhang X; Chen Z; Li X; Wei Q; Zhang P; Liu Z; Liu J; Zeng H Oncotarget; 2017 Aug; 8(33):55374-55383. PubMed ID: 28903426 [TBL] [Abstract][Full Text] [Related]
14. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Roy S; Sun Y; Morgan SC; Wallis CJD; King K; Zhou YM; D'souza LA; Azem O; Cueto-Marquez AE; Camden NB; Spratt DE; Kishan AU; Saad F; Malone S Eur Urol; 2023 Jun; 83(6):571-579. PubMed ID: 36894488 [TBL] [Abstract][Full Text] [Related]
15. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060 [TBL] [Abstract][Full Text] [Related]
16. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831 [TBL] [Abstract][Full Text] [Related]
18. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer. Dong B; Fan L; Wang Y; Chi C; Ma X; Wang R; Cai W; Shao X; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Kang X; Zhou L; Xue W Prostate; 2017 May; 77(13):1373-1380. PubMed ID: 28804908 [TBL] [Abstract][Full Text] [Related]
19. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]